Patents by Inventor Kevin Beam

Kevin Beam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220306727
    Abstract: The present invention relates to the field of antibody formulations. In particular, the present invention relates to specific methods of preparing masked antibodies with reduced aggregation. In some embodiments, the masked antibodies comprise anti-CD47 antibodies.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 29, 2022
    Applicant: Seagen Inc.
    Inventors: Elise Cunningham, Susan Lee, Danielle Leiske, Catherine Eakin, Kevin Beam, Lori Westendorf, Michael Feldhaus, Samuel Pearce Alcoba
  • Publication number: 20200063180
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Application
    Filed: September 17, 2019
    Publication date: February 27, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass
  • Patent number: 10457976
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 29, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass
  • Publication number: 20170159099
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Application
    Filed: November 21, 2014
    Publication date: June 8, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass